Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-08-07), TTY Biopharm Co's 9-Day RSI is 47.71.
The industry rank for TTY Biopharm Co's 9-Day RSI or its related term are showing as below:
ROCO:4105's 9-Day RSI is ranked worse than 53.01% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 51.15
vs ROCO:4105: 47.71
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
TTY Biopharm Co 9-Day RSI Related Terms
ROCO:4105 vs ZTS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a 9-Day RSI of 47.71 as of Aug. 07, 2026. According to the industry distribution chart, TTY Biopharm Co ranks #555 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is TTY Biopharm Co's 9-Day RSI too high?
TTY Biopharm Co's current 9-Day RSI is 47.71. The Drug Manufacturers industry median 9-Day RSI is 51.15. TTY Biopharm Co's value of 47.71 is 6.7% below this industry median. Based on the distribution chart, TTY Biopharm Co ranks #555 out of 1047 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, TTY Biopharm Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's 9-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #555 out of 1047 companies for 9-Day RSI. This places TTY Biopharm Co in the lower half of its industry. The industry median 9-Day RSI is 51.15. TTY Biopharm Co's value of 47.71 is 6.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 51.15, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current 9-Day RSI of 47.71 is 6.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 51.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current 9-Day RSI is 47.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.97, compared to a current price of NT$76.10 — trading 13.5% below its estimated fair value. The current 9-Day RSI is 47.71 and 6.7% below the Drug Manufacturers industry median of 51.15. TTY Biopharm Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current 9-Day RSI is 47.71 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$76.10 is trading 13.5% below its estimated GF Value™ of NT$87.97.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
9-Day RSI: 47.71
GF Value™: NT$87.97 vs. price of NT$76.10 (13.5% below fair value)
Industry Position: 6.7% below the Drug Manufacturers median (#555 of 1047)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
85GF Score
Get the complete analysis for ROCO:4105
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
